PubMed=4567231; DOI=10.1093/jnci/49.3.891
Minowada J., Onuma T., Moore G.E.
Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.
J. Natl. Cancer Inst. 49:891-895(1972)
PubMed=4547172; DOI=10.1093/jnci/53.3.655
Huang C.C., Hou Y., Woods L.K., Moore G.E., Minowada J.
Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia.
J. Natl. Cancer Inst. 53:655-660(1974)
PubMed=165156; DOI=10.1002/ijc.2910150217
Nilsson K., Ponten J.
Classification and biological nature of established human hematopoietic cell lines.
Int. J. Cancer 15:321-341(1975)
PubMed=6181032; DOI=10.1016/0198-8859(82)90037-4
Rabinowitz R., Weinstock J., Margalioth E.J., Ben-Bassat H., Schlesinger M.
Antigens specific for human T-lymphocytes detected by xenoantisera to HD-MAR cells: their differential expression on various T-cell lines.
Hum. Immunol. 4:219-228(1982)
PubMed=6198871; DOI=10.18926/AMO/32400
Oda T., Watanabe S., Nakamura T.
Type C virus particles produced in human T-cell lines derived from acute lymphoblastic leukemia and a leukemic T-lymphoid malignancy.
Acta Med. Okayama 37:529-533(1983)
PubMed=6200433; DOI=10.1007/BF00364762
Brodsky F.M.
A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.
Immunogenetics 19:179-194(1984)
PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)
PubMed=2846092; DOI=10.1182/blood.V72.5.1755.1755
Greenberg J.M., Gonzalez-Sarmiento R., Arthur D.C., Wilkowski C.W., Streifel B.J., Kersey J.H.
Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human T-lymphoid cell lines with rearrangement of chromosome 7.
Blood 72:1755-1760(1988)
PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)
PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)
PubMed=2144611; DOI=10.1128/MCB.10.10.5502
Cheng J., Haas M.
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.
Mol. Cell. Biol. 10:5502-5509(1990)
PubMed=1765142; DOI=10.1016/0014-5793(91)81402-t
Orita S., Saiga A., Takagi S., Tanaka T., Okumura K., Aono Y., Hinuma Y., Igarashi H.
A novel alternatively spliced viral mRNA transcribed in cells infected with human T cell leukemia virus type 1 is mainly responsible for expressing p21X protein.
FEBS Lett. 295:127-134(1991)
PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)
CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)
PubMed=8316623; DOI=10.2307/3578190
Evans H.H., Ricanati M., Horng M.-F., Jiang Q., Mencl J., Olive P.
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Radiat. Res. 134:307-315(1993)
PubMed=8127147
Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.
Interferon system defects in malignant T-cells.
Leukemia 8:425-434(1994)
PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)
DOI=10.11418/jtca1981.15.4_211
Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.
Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction.
Tissue Cult. Res. Commun. 15:211-219(1996)
PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)
PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x
Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.
p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Eur. J. Haematol. 56:313-318(1996)
PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)
PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)
PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5
Kawamura M., Ohnishi H., Guo S.X., Sheng X.-M., Minegishi M., Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M., Sekiya T., Hayashi Y.
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Leuk. Res. 23:115-126(1999)
PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)
PubMed=11021758; DOI=10.1038/sj.leu.2401891
Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia 14:1821-1832(2000)
DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)
PubMed=11986953; DOI=10.1038/sj.leu.2402485
O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
Leukemia 16:902-910(2002)
PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)
PubMed=15472075; DOI=10.1126/science.1102160
Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Science 306:269-271(2004)
PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)
PubMed=15901131; DOI=10.1016/j.prp.2005.01.002
Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.
Pathol. Res. Pract. 201:109-115(2005)
PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)
PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)
PubMed=17117183; DOI=10.1038/sj.bjc.6603447
Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J., Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Br. J. Cancer 95:1537-1544(2006)
PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
DOI=10.4172/2157-7145.S2-005
Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)
PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)
PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)
4001790116
